Topics

FDA OKs 3-drug combo regimen BPaL for drug-resistant tuberculosis

06:40 EDT 15 Aug 2019 | SmartBrief

TB Alliance's BPaL, a three-drug combination regimen consisting of Johnson & Johnson's bedaquiline, pretomanid and linezolid, -More

Original Article: FDA OKs 3-drug combo regimen BPaL for drug-resistant tuberculosis

NEXT ARTICLE

More From BioPortfolio on "FDA OKs 3-drug combo regimen BPaL for drug-resistant tuberculosis"

Quick Search

Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...